The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
Stocks rose sharply on Monday as Treasury yields rebounded, quelling fears of a possible recessionUS Marketsread more
Powell will have the opportunity if not to walk back the "mid-cycle" assessment then to at least provide some further explanation about what it means.Economyread more
J.P. Morgan estimates the average annual tariff cost per household will be $1,000 with the new round of Trump's tariffs.Marketsread more
Since its IPO 15 years ago, Google has become more and more powerful. Today, that power is being highly scrutinized.Technologyread more
Sequoia's Michael Moritz says that direct listings worked for Spotify and Slack and will become more common for companies with "courage and intelligence."Technologyread more
Shares of embattled utility PG&E plummeted after a judge ruled that a jury can decided whether it should pay up to $18 billion in damages.Marketsread more
The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
In a statement Monday, Barr named Kathleen Hawk Sawyer the new director of the Federal Bureau of Prisons.Politicsread more
A strong jobs market and tax cuts are helping to bolster consumer spending at restaurants. The National Restaurant Association projects overall industry sales will hit a high...Restaurantsread more
Lobbying disclosure reports show that Maria Ressa, who founded news website Rappler Inc. in the Philippines, has tapped two partners out of Covington & Burling to help her...Politicsread more
(Adds details on deal)
July 29 (Reuters) - Mylan NV confirmed on Monday that it would combine with Pfizer Inc's off-patent branded and generic established medicines business to form a global generic drugmaker.
Under the terms of the agreement, which is structured as an all-stock deal, each Mylan share would be converted into one share of the new company.
Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said.
The new company, which will be renamed and rebranded after the deal closes, will be led by Mylan's Chairman Robert Coury, who will serve as executive chairman of the new company.
Michael Goettler, group president of Upjohn, will be the chief executive officer and Heather Bresch, Mylan's CEO, will retire after the deal closes.
As part of the deal, Pfizer will separate its Upjohn unit in a tax-free spinoff and will simultaneously combine with Mylan.
Upjohn will issue $12 billion of debt at or prior to separation. After the deal closes, the new company will have about $24.5 billion of total debt outstanding.
Separately, Pfizer on Monday reported a 30% rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)